CD274 and neoplasm: The sample size of high-TMB PDAC patients treated with ICIs so far globally is quite small [49] but if the information of PD-L1 expression is added (28.41% of our samples showed a PD-L1 value > 1% either in tumor or in the immune cells), there is potential space for off-label use of immunotherapy in some specific cases.